{"id":28200,"date":"2026-02-12T04:17:48","date_gmt":"2026-02-12T04:17:48","guid":{"rendered":"https:\/\/blogemergencias.es\/index.php\/2026\/02\/12\/can-ruti-estrena-un-farmaco-que-prolonga-la-supervivencia-de-enfermos-de-un-tipo-de-ela\/"},"modified":"2026-02-12T04:17:48","modified_gmt":"2026-02-12T04:17:48","slug":"can-ruti-estrena-un-farmaco-que-prolonga-la-supervivencia-de-enfermos-de-un-tipo-de-ela","status":"publish","type":"post","link":"https:\/\/blogemergencias.es\/index.php\/2026\/02\/12\/can-ruti-estrena-un-farmaco-que-prolonga-la-supervivencia-de-enfermos-de-un-tipo-de-ela\/","title":{"rendered":"Can Ruti estrena un f\u00e1rmaco que prolonga la supervivencia de enfermos de un tipo de ELA"},"content":{"rendered":"<div><!--[--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El <a class=\"ft-link ft-link--decoration broken_link\" href=\"https:\/\/www.elperiodico.com\/es\/temas\/hospital-can-ruti-germans-trias-25552\" target=\"_blank\"><strong>Hospital Germans Trias i Pujol, Can Ruti,<\/strong><\/a><strong> <\/strong>ha administrado por primera vez un<strong> f\u00e1rmaco pionero en Europa<\/strong> que prolonga la supervivencia de enfermos de un <strong>tipo concreto de <\/strong><a class=\"ft-link ft-link--decoration broken_link\" href=\"https:\/\/www.elperiodico.com\/es\/temas\/esclerosis-lateral-amiotrofica-ela-26692\" target=\"_blank\"><strong>ELA (esclerosis lateral amiotr\u00f3fica),<\/strong><\/a><strong> <\/strong>al aumentar la fuerza muscular y la capacidad respiratoria de los pacientes.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><\/p>\n<aside class=\"ft-ad ft-ad--roba ft-ad--robaNotext ft-helper-hide-md\" style=\"\"\/><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">En una nota de prensa, este hospital de <strong>Badalona <\/strong>(Barcelona) ha informado este martes de que est\u00e1 tratando a un<strong> primer paciente, de 44 a\u00f1os, <\/strong>con este f\u00e1rmaco, llamado Tofersen, que ralentiza la evoluci\u00f3n de una variante gen\u00e9tica de la esclerosis lateral amiotr\u00f3fica.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!--[--><!----><!----><!--]--><!----><!----><!----><!----><!----><!--[--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext ft-helper-hide-md\"\/><!--]--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext  ft-helper-hide-xs\"\/><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Fuentes de Can Ruti han asegurado que el hospital se encuentra <strong>entre los primeros de Espa\u00f1a <\/strong>en aplicar este tratamiento, indicado para pacientes diagnosticados de ELA por una mutaci\u00f3n del gen SOD1, lo que representa un 2% de todos los casos y que supone la segunda causa m\u00e1s frecuente de la ELA gen\u00e9tica.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">La terapia, recientemente aprobada, se ha demostrado <strong>eficaz <\/strong>al suponer una mejora de la calidad de vida para los enfermos de esta variante, la segunda causa m\u00e1s frecuente de ELA hereditaria o gen\u00e9tica en la poblaci\u00f3n.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><\/p>\n<aside class=\"ft-ad ft-ad--roba ft-ad--robaNotext ft-helper-hide-md\" style=\"\"\/><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Las tres primeras dosis del f\u00e1rmaco, cuyo uso se aprob\u00f3 despu\u00e9s de un ensayo cl\u00ednico internacional, se administran mediante <strong>punci\u00f3n lumbar cada 15 d\u00edas<\/strong> y otras mensualmente.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!----><!----><!----><!----><\/p>\n<h3 class=\"ft-helper-spacer-t-xs ft-helper-fontSize-heading-XS\">\u00abUna nueva etapa en el tratamiento\u00bb<\/h3>\n<p><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Seg\u00fan la especialista de la Unidad de Experiencia Cl\u00ednica de Enfermedades Minoritarias Neuromusculares del Germans Trias M\u00edriam Almendrote, este nuevo tratamiento supone un cambio en la forma en que se aborda la enfermedad: \u00abLlevamos muchos a\u00f1os <strong>acompa\u00f1ando a personas y familias afectadas por la ELA,<\/strong> y hasta ahora las opciones terap\u00e9uticas eran muy limitadas. Este f\u00e1rmaco, aunque no es una cura, s\u00ed es capaz de modificar la evoluci\u00f3n de la enfermedad en un subgrupo concreto de pacientes\u00bb, asegura.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext ft-helper-hide-md\"\/><!--]--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext  ft-helper-hide-xs\"\/><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Para Almendrote, se trata de <strong>\u00abun avance esperanzador <\/strong>que abre la puerta a una nueva etapa en el tratamiento de esta patolog\u00eda\u00bb.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!----><!----><!----><!----><\/p>\n<h3 class=\"ft-helper-spacer-t-xs ft-helper-fontSize-heading-XS\">Casi 30 a\u00f1os desde la \u00faltima terapia<\/h3>\n<p><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Esta terapia es la primera autorizada por la Uni\u00f3n Europea para la ELA desde 1996.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><\/p>\n<aside class=\"ft-ad ft-ad--roba ft-ad--robaNotext ft-helper-hide-md\" style=\"\"\/><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Precisamente, la <strong>Agencia Europea del Medicamento <\/strong>aprob\u00f3 en 2024 el uso de este f\u00e1rmaco, aunque el Ministerio de Sanidad lo financia hace pocos meses.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!--[--><!----><!----><!--]--><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">A pesar de ser minoritaria, la ELA es la tercera <strong>enfermedad neurodegenerativa<\/strong> m\u00e1s frecuente en Catalunya, por debajo de la demencia y el Parkinson, y no hay una cura para ella.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--]--><!--[--><!----><!--[--><!--]--><!----><!--[--><!----><!----><!----><!--]--><span\/><!--]--><\/div>\n<p><a href=\"https:\/\/www.elperiodico.com\/es\/sanidad\/20260211\/can-ruti-estrena-farmaco-prolonga-enfermos-ela-126714638?utm_source=rss-noticias&amp;utm_medium=feed&amp;utm_campaign=sanidad\" class=\"broken_link\">source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El Hospital Germans Trias i Pujol, Can Ruti, ha administrado por primera vez un f\u00e1rmaco pionero en Europa<\/p>\n","protected":false},"author":1,"featured_media":28201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_joinchat":[],"footnotes":""},"categories":[1],"tags":[],"class_list":["post-28200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"featured_image_urls":{"full":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400.png",1200,675,false],"thumbnail":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400-150x150.png",150,150,true],"medium":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400-300x169.png",300,169,true],"medium_large":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400-768x432.png",640,360,true],"large":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400-1024x576.png",640,360,true],"1536x1536":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400.png",1200,675,false],"2048x2048":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400.png",1200,675,false],"morenews-large":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400-825x575.png",825,575,true],"morenews-medium":["https:\/\/blogemergencias.es\/wp-content\/uploads\/2026\/02\/wp-header-logo-400-590x410.png",590,410,true]},"author_info":{"info":["admin"]},"category_info":"<a href=\"https:\/\/blogemergencias.es\/index.php\/category\/noticias\/\" rel=\"category tag\">Noticias<\/a>","tag_info":"Noticias","comment_count":0,"_links":{"self":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/posts\/28200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/comments?post=28200"}],"version-history":[{"count":0,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/posts\/28200\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/media\/28201"}],"wp:attachment":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/media?parent=28200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/categories?post=28200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/tags?post=28200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}